[1] Hoofnagle J H, Bjornsson E S. Drug-induced liver injury-types and phenotypes[J]. N Engl J Med, 2019, 381(3): 264-273.
[2] 于乐成, 茅益民, 陈成伟. 药物性肝损伤诊治指南[J]. 临床肝胆病杂志, 2015, 31(11): 1752-1769.
[3] Andrade R J, Chalasani N, Bjornsson E S, et al. Drug-induced liver injury[J]. Nat Rev Dis Primers, 2019, 5(1): 58.
[4] 杨瑞园, 赵新颜. 肝组织病理学检查在药物性肝损伤诊治中的意义[J]. 临床肝胆病杂志, 2018, 34(6): 1172-1175.
[5] Gasmi B, Kleiner D E. Liver histology: diagnostic and prognostic features[J]. Clin Liver Dis, 2020, 24(1): 61-74.
[6] Kleiner D E. The histopathological evaluation of drug-induced liver injury[J]. Histopathology, 2017, 70(1): 81-93.
[7] Kleiner D E, Chalasani N P, Lee W M, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations[J]. Hepatology, 2014, 59(2): 661-670.
[8] Ahmad J, Barnhart H X, Bonacini M, et al. Value of liver biopsy in the diagnosis of drug-induced liver injury[J]. J Hepatol, 2022, 76(5): 1070-1078.
[9] Teschke R, Schulze J, Eickhoff A, et al. Drug induced liver injury: can biomarkers assist RUCAM in causality assessment?[J]. Int J Mol Sci, 2017, 18(4):803.
[10] Rutherford A E, Hynan L S, Borges C B, et al. Serum apoptosis markers in acute liver failure: a pilot study[J]. Clin Gastroenterol Hepatol, 2007, 5(12): 1477-1483.
[11] Pisetsky D S, Jiang W. Role of Toll-like receptors in HMGB1 release from macrophages[J]. Ann N Y Acad Sci, 2007, 1109: 58-65.
[12] Adams D H, Ju C, Ramaiah S K, et al. Mechanisms of immune-mediated liver injury[J]. Toxicol Sci, 2010, 115(2): 307-321.
[13] Benesic A, Rotter I, Dragoi D, et al. Development and validation of a test to identify drugs that cause idiosyncratic drug-induced liver injury[J]. Clin Gastroenterol Hepatol, 2018, 16(9): 1488-1494. e1485.
[14] Vliegenthart A D B, Berends C, Potter C M J, et al. MicroRNA-122 can be measured in capillary blood which facilitates point-of-care[J]. Br J Clin Pharmacol, 2017, 83(9): 2027-2033.
[15] Miller T J, Knapton A, Adeyemo O, et al. Cytochrome c: a non-invasive biomarker of drug-induced liver injury[J]. J Appl Toxicol, 2008, 28(7): 815-828.
[16] Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update[J]. Int J Mol Sci, 2015, 17(1):14.
[17] 于乐成, 范晔. RUCAM诊断药物性肝损伤的进展及其与结构化专家观点评估法的比较[J]. 临床肝胆病杂志, 2016, 32(9): 1706-1713.
[18] 陈成伟. 认真回顾研究史重视RUCAM量表在药物性肝损伤诊断中的应用[J]. 中华肝脏病杂志, 2016, (11): 801-803.
[19] 赖荣陶, 陈成伟, 阳文新, 等. 药物性肝损伤因果关系评估量表:RECAM将取代RUCAM?[J]. 肝脏, 2022, 27(7): 725-729.
[20] Hayashi P H, Lucena M I, Fontana R J, et al. A revised electronic version of RUCAM for the diagnosis of DILI[J]. Hepatology, 2022, 76(1): 18-31.
[21] Lewis J H. Digitizing DILI: Who can? RUCAM? RECAM?[J]. Hepatology, 2022, 76(1): 3-5.
[22] Fontana R J, Watkins P B, Bonkovsky H L, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct[J]. Drug Saf, 2009, 32(1): 55-68.
[23] Hayashi P H, Barnhart H X, Fontana R J, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN)[J]. Liver Int, 2015, 35(5): 1623-1632.
[24] Hayashi P H. Drug-Induced Liver Injury Network causality assessment: criteria and experience in the united states[J]. Int J Mol Sci, 2016, 17(2): 201.
[25] Rockey D C, Seeff L B, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method[J]. Hepatology, 2010, 51(6): 2117-2126.
[26] Aithal G P, Rawlins M D, Day C P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions[J]. J Hepatol, 2000, 33(6): 949-952.
[27] Tajiri K, Shimizu Y. Practical guidelines for diagnosis and early management of drug-induced liver injury[J]. World J Gastroenterol, 2008, 14(44): 6774-6785.
[28] Das S, Behera S K, Xavier A S, et al. Agreement among different scales for causality assessment in drug-induced liver injury[J]. Clin Drug Investig, 2018, 38(3): 211-218.
[29] Lucena M I, Camargo R, Andrade R J, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity[J]. Hepatology, 2001, 33(1): 123-130.
[30] 何婷婷, 梁庆升, 王丽苹, 等. 整合证据链、Roussel Uclaf因果关系评价法、结构化专家观点程序对药物性肝损伤的诊断效用分析[J]. 临床肝胆病杂志, 2022, 38(1): 141-147.
[31] Takikawa H, Takamori Y, Kumagi T, et al. Assessment of 287 Japanese cases of drug induced liver injury by the diagnostic scale of the International Consensus Meeting[J]. Hepatol Res, 2003, 27(3): 192-195.
[32] Watanabe M, Shibuya A. Validity study of a new diagnostic scale for drug-induced liver injury in Japan-comparison with two previous scales[J]. Hepatol Res, 2004, 30(3): 148-154.
[33] Hanatani T, Sai K, Tohkin M, et al. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the Council for International Organizations of Medical Sciences/the Roussel Uclaf Causality Assessment Method scale[J]. Pharmacoepidemiol Drug Saf, 2014, 23(9): 984-988.
[34] Tsutsui A, Nakanuma Y, Takaguchi K, et al. Comparison of liver biopsy findings with the digestive disease week Japan 2004 scale for diagnosis of drug-induced liver injury[J]. Mediators Inflamm, 2015, 2015: 913793.
[35] Watanabe M, Shibuya A, Yokomori H, et al. The diagnosis of drug-induced liver injury: current diagnostic ability and future challenges of the digestive disease week-Japan 2004 scale 15 years after its proposal[J]. Intern Med, 2021, 60(16): 2557-2568.
[36] Garcia-Cortes M, Lucena M I, Pachkoria K, et al. Evaluation of naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury[J]. Aliment Pharmacol Ther, 2008, 27(9): 780-789.
[37] Li Z B, Chen D D, He Q J, et al. The LAC score indicates significant fibrosis in patients with chronic drug-induced liver injury: a large biopsy-based study[J]. Frontiers in Pharmacology, 2021, 12: 734090. |
